Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | KMT2A |
| Variant | fusion |
| Impact List | fusion |
| Protein Effect | unknown |
| Gene Variant Descriptions | KMT2A fusion indicates a fusion of the KMT2A gene, but the fusion partner is unknown. |
| Associated Drug Resistance | |
| Category Variants Paths |
KMT2A mutant KMT2A rearrange KMT2A fusion |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07355335 | Phase I | CC-92480 + Ziftomenib | Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML | Not yet recruiting | USA | 0 |
| NCT02487459 | Phase I | Rivogenlecleucel Rimiducid | Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies | Withdrawn | USA | 0 |
| NCT04988555 | Phase Ib/II | DSP-5336 | A Study of DSP-5336 in Relapsed/refractory AML/ ALL with or Without MLL Rearrangement or NPM1 Mutation | Recruiting | USA | ITA | GBR | FRA | ESP | CAN | BEL | 4 |